Geron (NASDAQ:GERN) Releases Earnings Results, Beats Expectations By $0.05 EPS

Geron (NASDAQ:GERN) posted its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.09) by $0.05, Briefing.com reports. The firm had revenue of $28.27 million for the quarter, compared to the consensus estimate of $18.97 million. Geron had a negative net margin of 15,990.68% and a negative return on equity of 73.79%. The company’s revenue for the quarter was up 17138.4% on a year-over-year basis. During the same period last year, the firm posted ($0.08) earnings per share.

Geron Trading Down 0.9 %

GERN stock traded down $0.04 during mid-day trading on Friday, hitting $4.25. 12,136,906 shares of the company were exchanged, compared to its average volume of 10,462,808. Geron has a 12-month low of $1.64 and a 12-month high of $5.34. The firm has a market capitalization of $2.56 billion, a P/E ratio of -13.28 and a beta of 0.52. The business has a fifty day simple moving average of $4.32 and a 200-day simple moving average of $4.30. The company has a quick ratio of 3.60, a current ratio of 3.61 and a debt-to-equity ratio of 0.12.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on GERN shares. Scotiabank began coverage on shares of Geron in a research note on Wednesday, October 16th. They issued a “sector outperform” rating and a $6.00 target price on the stock. StockNews.com raised Geron to a “sell” rating in a report on Monday, August 5th. Leerink Partners initiated coverage on Geron in a research note on Monday, September 9th. They set an “outperform” rating and a $7.00 price objective on the stock. Needham & Company LLC reaffirmed a “buy” rating and issued a $6.00 target price on shares of Geron in a research note on Friday, August 9th. Finally, Leerink Partnrs upgraded Geron to a “strong-buy” rating in a report on Monday, September 9th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $7.05.

About Geron

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.